Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Vertosa Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio is currently navigating 1 pending office action. This 1 pending office action is the only active matter for the company, suggesting a focused effort on a specific technical filing.
The prosecution is overseen by 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company's innovations are being reviewed within a single technical division by a single individual. For the practitioner, the 1 distinct examiner and 1 distinct art unit provide a consistent environment where the prosecution strategy can be refined for a single audience without competing procedural requirements.
BORI, IBRAHIM D is the busiest examiner, managing 1 busiest examiner pending office action. Because BORI, IBRAHIM D is the only examiner involved, the success of the 1 pending office action depends entirely on this individual's assessment. Practitioners should focus on the specific examination patterns of BORI, IBRAHIM D to move the portfolio forward effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18750843 | HIGH POTENCY EMULSIONS | BORI, IBRAHIM D | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18750843 | HIGH POTENCY EMULSIONS | BORI, IBRAHIM D | 1629 | — | Final Rejection | 9d overdue | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial